M2Bio Building A World Class Supply Chain Solution - Dr. Southey and Dr. Zarrebini Update on M2Bio Blockchain and Technology Group
Wuhan General Group, Inc. (OTC PINK: WUHN) reported progress on its Blockchain Supply Chain solution through its M2Bio Blockchain Research & Technology Group. Phase I has been completed, and Phase II is underway, aiming to disrupt current supply chain models. The blockchain solution offers enhanced security, trust in manufacturing, and integration with advanced technologies like IoT and AI. The platform is designed to accommodate various industries and support ESG principles. New webinars will be held in November and December 2021 to discuss its developments.
- Completion of Phase I development of the Blockchain Supply Chain solution.
- Aiming to disrupt established competitors such as Oracle, SAP, and Amazon.
- Integration with advanced technologies like IoT and AI planned.
- None.
CAPE TOWN, SA / ACCESSWIRE / October 25, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:
The M2Bio Blockchain Research & Technology Group is delighted to have completed Phase I development of the Company's Blockchain Supply Chain solution, with Phase II already underway. Using cutting-edge technology in highly innovative ways, the M2Bio supply chain platform aims to disrupt the currently available alternatives.
"Our in-depth research has exposed multiple vulnerabilities and inefficiencies in present centralized supply chain offerings, and we are confident that the model we have designed will be a significant competitor to the likes of Oracle, SAP, and Amazon," say Dr. Southey and Dr. Zarrebini, Directors of the M2Bio Blockchain Research and Technology Group.
At the basic level, the solution enables seamless onboarding to a private blockchain environment which supports trust in manufacturing and product provenance for all stakeholders and end-consumers in the supply chain. Advanced security, granular permission systems, and the use of smart contracts will enable privacy-preserving business processes to continue whilst maintaining real-time visibility to privileged partners.
Dr. Southey explains that "We are at a point in the evolution of this technology where, having watched others develop solutions, we are able to pick the best from private and public chains and create a truly unique model that not only trumps the centralized incumbents but also outperforms other blockchain alternatives."
The Group plans to incorporate micropayments, tokenization, and other advanced technologies including IoT and Artificial Intelligence into the technology. "We are also excited to be building a solution that supports ESG principles by design. Sustainability and recycling visibility in the ‘Consumption Chain' are incredibly important components of good governance, and we believe these to be a core requirement in modern supply chain management solutions", said Dr. Zarrebini.
Although initially being designed for M2Bio, the solution will be easily integrated into all legacy systems across multiple sectors and aims to provide a true leap in value for supply chain users in any industry.
M2Bio Sciences CEO and Founder Jeff Robinson explains "The M2Bio Blockchain Supply Chain solution will revolutionize the current supply chain management systems. We are stoked to see our state-of-the-art technology and IP roll out across multiple platforms and applications internationally. It offers innovative solutions to current defects in similar existing product offerings and the demand for these solutions are a reality."
The M2Bio Blockchain Research and Technology Group will host several webinars on groundbreaking technology throughout the months of November and December 2021.
Sign up here to get notifications on the latest company updates and schedules for the upcoming webinars.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".
Publicly traded company (OTC PINK: WUHN)
Website: www.m2bio.co
E-mail:info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio
Follow us on Instagram: https://www.instagram.com/m2bio.sciences
Forward-Looking Statements:
Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc. / M2Bio Sciences, Inc
View source version on accesswire.com:
https://www.accesswire.com/669460/M2Bio-Building-A-World-Class-Supply-Chain-Solution--Dr-Southey-and-Dr-Zarrebini-Update-on-M2Bio-Blockchain-and-Technology-Group
FAQ
What is the latest news from Wuhan General Group (WUHN) regarding blockchain?
How does the M2Bio Blockchain Supply Chain solution aim to improve current supply chains?
What are the future plans for the M2Bio Blockchain Supply Chain technology?
What companies does Wuhan General Group aim to compete with in the blockchain space?
